Open-Label Study of AG10 in Patients with Cardiomyopathy
An Open-Label Extension and Safety Monitoring Study of Patients with Symptomatic Transthyretin Cardiomyopathy Who Have Completed the Phase II Study AG10-201
Sponsor: Eidos Therapeutics, a BridgeBio company
A PHASE2 clinical study on Amyloid Cardiomyopathy, this trial is ongoing. The trial is conducted by Eidos Therapeutics, a BridgeBio company and has accumulated 11 data snapshots since 2018. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
11 versions recorded-
Apr 2025 — Present [monthly]
Active Not Recruiting PHASE2
-
Sep 2024 — Apr 2025 [monthly]
Active Not Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE2
-
Mar 2023 — Jul 2024 [monthly]
Active Not Recruiting PHASE2
-
Oct 2021 — Mar 2023 [monthly]
Active Not Recruiting PHASE2
Status: Enrolling By Invitation → Active Not Recruiting
▶ Show 6 earlier versions
-
Jan 2021 — Oct 2021 [monthly]
Enrolling By Invitation PHASE2
-
Dec 2019 — Jan 2021 [monthly]
Enrolling By Invitation PHASE2
-
May 2019 — Dec 2019 [monthly]
Enrolling By Invitation PHASE2
-
Sep 2018 — May 2019 [monthly]
Enrolling By Invitation PHASE2
-
Aug 2018 — Sep 2018 [monthly]
Enrolling By Invitation PHASE2
-
Jun 2018 — Aug 2018 [monthly]
Enrolling By Invitation PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Eidos Therapeutics, a BridgeBio company
For direct contact, visit the study record on ClinicalTrials.gov .